Literature DB >> 21170290

Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Zaklyah Kadry1, Oscar Bronsther, David H Van Thiel, Parmjeet Randhawa, John J Fung, Thomas E Starzl.   

Abstract

Of 1463 liver allograft recipients receiving the combination of FK506 and steroids as their primary immunosuppressive regimen, 2 patients developed Kaposi's sarcoma. Although previously described as a complication of organ transplantation, this is the first case report of Kaposi's sarcoma occurring in association with the macrolide immunosuppressive agent FK506. A discussion of the clinical presentation and course of Kaposi's sarcoma in these 2 patients, as well as a review of the past literature on Kaposi's sarcoma in organ transplant recipients, emphasizes the therapeutic difficulties encountered. Kaposi's sarcoma is also compared to lymphoproliferative disorders, another well-recognized complication of immunosuppression, highlighting the differences between these two entities.

Entities:  

Year:  1993        PMID: 21170290      PMCID: PMC3002425     

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  25 in total

Review 1.  Kaposi's sarcoma unrelated to the acquired immunodeficiency syndrome.

Authors:  M R Wick
Journal:  Curr Opin Oncol       Date:  1991-04       Impact factor: 3.645

Review 2.  Severe lymphoproliferative disease and Kaposi sarcoma in transplant patients.

Authors:  J L Touraine; J L Garnier; N Lefrancois; J Finaz de Villaine; J M Dubernard; G de Thé; G Lenoir
Journal:  Transplant Proc       Date:  1989-02       Impact factor: 1.066

Review 3.  Interferon and other biologic agents for the treatment of Kaposi's sarcoma.

Authors:  S E Krown
Journal:  Hematol Oncol Clin North Am       Date:  1991-04       Impact factor: 3.722

4.  Antibody patterns to herpesviruses in kaposi's sarcoma: serological association of european kaposi's sarcoma with cytomegalovirus.

Authors:  G Giraldo; E Beth; F M Kourilsky; W Henle; G Henle; V Miké; J M Huraux; H K Andersen; M R Gharbi; S K Kyalwazi; A Puissant
Journal:  Int J Cancer       Date:  1975-05-15       Impact factor: 7.396

Review 5.  The diagnosis and treatment of posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; L Makowka; T E Starzl
Journal:  Curr Probl Surg       Date:  1988-06       Impact factor: 1.909

Review 6.  The role of interferon in the therapy of epidemic Kaposi's sarcoma.

Authors:  S E Krown
Journal:  Semin Oncol       Date:  1987-06       Impact factor: 4.929

Review 7.  Kaposi's sarcoma: its 'oncogenes' and growth factors.

Authors:  J G Sinkovics
Journal:  Crit Rev Oncol Hematol       Date:  1991       Impact factor: 6.312

8.  Kaposi's sarcoma in organ transplant recipients: report of 20 cases.

Authors:  I Penn
Journal:  Transplantation       Date:  1979-01       Impact factor: 4.939

9.  Interferon alfa-2a therapy for life-threatening hemangiomas of infancy.

Authors:  R A Ezekowitz; J B Mulliken; J Folkman
Journal:  N Engl J Med       Date:  1992-05-28       Impact factor: 91.245

10.  Hepatitis B virus DNA in Kaposi sarcoma.

Authors:  A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.